[(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

Sandhu S, Joshua AM, Emmett L, Bressel M, Anton A, Spain L, Horvath LG, Pasam A, Tolmeijer SH, Akhurst TJ, Alipour R, Banks P, Buteau JP, Cassidy E, Crumbaker M, Dhiantravan N, Xu W, Chan J, Hitchen N, Scalzo M, Ravi Kumar AS, Kong G, Wallace R, Williams N, Williams S, Haynes NM, Neeson P, Wyatt AW, Hicks RJ, Hofman MS

Open source

DOI: 10.1016/s1470-2045(26)00017-3
Published: 2026 Apr
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00017-3,
  title = {[(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.},
  author = {Sandhu S and Joshua AM and Emmett L and Bressel M and Anton A and Spain L and Horvath LG and Pasam A and Tolmeijer SH and Akhurst TJ and Alipour R and Banks P and Buteau JP and Cassidy E and Crumbaker M and Dhiantravan N and Xu W and Chan J and Hitchen N and Scalzo M and Ravi Kumar AS and Kong G and Wallace R and Williams N and Williams S and Haynes NM and Neeson P and Wyatt AW and Hicks RJ and Hofman MS},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00017-3},
  url = {https://doi.org/10.1016/s1470-2045(26)00017-3}
}

RIS

TY  - JOUR
TI  - [(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
AU  - Sandhu S
AU  - Joshua AM
AU  - Emmett L
AU  - Bressel M
AU  - Anton A
AU  - Spain L
AU  - Horvath LG
AU  - Pasam A
AU  - Tolmeijer SH
AU  - Akhurst TJ
AU  - Alipour R
AU  - Banks P
AU  - Buteau JP
AU  - Cassidy E
AU  - Crumbaker M
AU  - Dhiantravan N
AU  - Xu W
AU  - Chan J
AU  - Hitchen N
AU  - Scalzo M
AU  - Ravi Kumar AS
AU  - Kong G
AU  - Wallace R
AU  - Williams N
AU  - Williams S
AU  - Haynes NM
AU  - Neeson P
AU  - Wyatt AW
AU  - Hicks RJ
AU  - Hofman MS
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00017-3
UR  - https://doi.org/10.1016/s1470-2045(26)00017-3
ER  -

APA

S, S., AM, J., L, E., M, B., A, A., L, S., LG, H., A, P., SH, T., TJ, A., R, A., P, B., JP, B., E, C., M, C., N, D., W, X., J, C., N, H., M, S., AS, R. K., G, K., R, W., N, W., S, W., NM, H., P, N., AW, W., RJ, H., & MS, H. (2026). [(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00017-3

Source records

pubmed · retrieved 2026-09-26T20:24:35.326Z